Litcius/Paper detail

Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient

Sara Gómez-Enjuto, Virgilio Hernando‐Requejo, J. Lapeña-Motilva, G. Ogando-Durán, Daniel Fouz-Ruiz, Julio Domingo-García, Elena Rodríguez-García, Carlos Alberto Cemillán-Fernández

2020Seizure26 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDexamethasoneRitonavirCeftriaxoneLopinavirInternal medicineBlood pressureMethylprednisoloneAnesthesiaGastroenterologySurgeryPediatricsViral loadCoronavirus disease 2019 (COVID-19)ImmunologyHuman immunodeficiency virus (HIV)Antiretroviral therapyInfectious disease (medical specialty)DiseaseMicrobiologyAntibioticsBiologyPharmacological Effects and Toxicity StudiesNeurological Complications and SyndromesHemoglobinopathies and Related Disorders
Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient | Litcius